Drug intelligence / Profile preview

mitizodone

Development stage: Phase 3
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

Mitizodone is an investigational small molecule developed for the treatment of major depressive disorder. It functions as a serotonin reuptake inhibitor and a partial agonist of the serotonin 5-HT1A receptor, aiming to enhance serotonergic neurotransmission. Developed by Sunshine Lake Pharma and initially by Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd., mitizodone is currently in Phase 3 clinical trials, primarily targeting approval in China. It is administered orally as tablets.

Brand names: Mitizodone phosphate tablets
Other names: Mitizodone Phosphate

Targets

SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on mitizodone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitizodone.

Explore the full profile